Objective To compare two quality improvement (QI) interventions to improve antenatal
magnesium sulphate (MgSO4) uptake in preterm births for the prevention of cerebral palsy …

Objective To investigate the impact of an enhanced QI support programme (ESP) in further
improving the magnesium sulphate (MgSO4) uptake compared to the National PReCePT …

Objective To evaluate the effectiveness and cost-effectiveness of the National PReCePT
Programme (NPP) in increasing use of magnesium sulfate (MgSO4) in preterm births …

The UK's National Institute for Health and Care Excellence Preterm labour and birth
guideline recommends use of magnesium sulfate (MgSO4) in deliveries below 30 weeks' …

Magnesium sulphate has been demonstrated to be an effective neuroprotectant for babies
delivered prematurely (under 37 weeks' gestational age). Antenatal administration reduces …

Magnesium sulfate given to women before birth at< 30 weeks' gestation reduces the risk of
cerebral palsy in their children. Our study aimed to assess the impact of a local quality …

Background Evidence supports magnesium sulphate (MgSO4) for women at risk of imminent
birth at< 32–34 weeks to reduce the likelihood of cerebral palsy in the child. MAGnesium …

Objective To study the effect of antenatal magnesium sulphate (MgSO4) on cerebral palsy
(CP) in a manner that also provides adequate power for a linked trial sequential analysis …

Background Administration of magnesium sulphate (MgSO 4) to women with imminent
preterm birth at< 34 weeks is an evidence-based antenatal neuroprotective strategy to …

Background: Methods for the economic evaluation of implementation initiatives to increase
the uptake of cost-effective healthcare interventions are not standardised. Value of …